Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/CT in patients with glioma
- 148 Downloads
The potential of positron emission tomography/computed tomography using 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) (62Cu-ATSM PET/CT), which was originally developed as a hypoxic tracer, to predict therapeutic resistance and prognosis has been reported in various cancers. Our purpose was to investigate prognostic value of 62Cu-ATSM PET/CT in patients with glioma, compared to PET/CT using 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG).
56 patients with glioma of World Health Organization grade 2–4 were enrolled. All participants had undergone both 62Cu-ATSM PET/CT and 18F-FDG PET/CT within mean 33.5 days prior to treatment. Maximum standardized uptake value and tumor/background ratio were calculated within areas of increased radiotracer uptake. The prognostic significance for progression-free survival and overall survival were assessed by log-rank test and Cox’s proportional hazards model.
Disease progression and death were confirmed in 37 and 27 patients in follow-up periods, respectively. In univariate analysis, there was significant difference of both progression-free survival and overall survival in age, tumor grade, history of chemoradiotherapy, maximum standardized uptake value and tumor/background ratio calculated using 62Cu-ATSM PET/CT. Multivariate analysis revealed that maximum standardized uptake value calculated using 62Cu-ATSM PET/CT was an independent predictor of both progression-free survival and overall survival (p < 0.05). In a subgroup analysis including patients of grade 4 glioma, only the maximum standardized uptake values calculated using 62Cu-ATSM PET/CT showed significant difference of progression-free survival (p < 0.05).
62Cu-ATSM PET/CT is a more promising imaging method to predict prognosis of patients with glioma compared to 18F-FDG PET/CT.
Keywords62Cu-ATSM PET/CT 18F-FDG PET/CT Glioma Tumor progression Survival
This work was supported by a Grant-in-Aid for Cancer Research (21-5-2) from the Ministry of Health, Labor and Welfare and was also supported in part by the Ministry of Education, Culture, Sports, Science and Technology, KAKENHI Grant (15K19977 to Makoto Ohtake). In addition, this work was supported in part by grants from Scientific Research Expenses for Health and Welfare Programs, the Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, No. 15K09885, the Scientific Research Expenses for Health and Welfare Programs, No. 29-A-3 (Takashi Terauchi and Ukihide Tateishi: squad leaders), Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs by Japan Agency for Medical Research and Development (AMED).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, et al. Application of 62Cu-diacetyl-bis (N 4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma. AJNR Am J Neuroradiol. 2013;34:92 – 9.CrossRefPubMedGoogle Scholar
- 9.Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51:1641–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Tateishi K, Tateishi U, Nakanowatari S, Ohtake M, Minamimoto R, Suenaga J, et al. 62Cu-diacetyl-bis (N 4-methylthiosemicarbazone) PET in human gliomas: comparative study with [18F]fluorodeoxyglucose and l-methyl-[11C]methionine PET. AJNR Am J Neuroradiol. 2014;35:278 – 84.CrossRefPubMedGoogle Scholar
- 16.Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomilly R, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002;42:1667–73.Google Scholar
- 20.Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N 4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–502.CrossRefPubMedGoogle Scholar
- 28.Bonekamp D, Deike K, Wiestler B, Wick W, Bendszus M, Radbruch A, et al. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1- and T2 *-based bolus techniques. J Magn Reson Imaging. 2015;42:87–96.CrossRefPubMedGoogle Scholar